


PHARMACEUTICAL 2022

Zentalis Pharmaceuticals Inc. Rank 239 of 475





PHARMACEUTICAL 2022

Zentalis Pharmaceuticals Inc. Rank 239 of 475

The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Zentalis Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -95%, being 181% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	350,770
Cost of Goods Sold	0
Intangible Assets	3,736
Liabilities, Current	43,944
Liabilities, Non-Current	44,459
Other Assets	91,853
Other Compr. Net Income	7,207
Other Expenses	-297
Other Liabilities	1,622
Other Net Income	50,152
Property and Equipment	8,148
Research and Development	175,601
Revenues	0
Selling, General and Administrative Expense	40,941

Output Variable	Value in 1000 USD
Assets	454,507
Liabilities	90,025
Expenses	216,245
Stockholders Equity	364,482
Net Income	-166,093
Comprehensive Net Income	-162,490
Economic Capital Ratio	-95%